Axsome Therapeutics, Inc. (0HKF.L)
USD 99.91
(7.08%)
USD 99.91
(7.08%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 244.53 Million USD | 430.12% |
| 2022 | 44.83 Million USD | 3979.98% |
| 2021 | -1.15 Million USD | -1387.0% |
| 2020 | -77.71 Thousand USD | -108.19% |
| 2019 | -37.33 Thousand USD | 23.72% |
| 2018 | -48.93 Thousand USD | -14.99% |
| 2017 | -42.55 Thousand USD | -107.76% |
| 2016 | -20.48 Thousand USD | -478.32% |
| 2015 | -3542.00 USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 66.87 Million USD | 4.24% |
| 2024 Q2 | 77.25 Million USD | 18.3% |
| 2023 Q2 | 42.1 Million USD | -51.62% |
| 2023 Q4 | 64.15 Million USD | 25.15% |
| 2023 Q3 | 51.26 Million USD | 21.76% |
| 2023 Q1 | 87.02 Million USD | 294.1% |
| 2023 FY | 237.7 Million USD | 430.12% |
| 2022 Q4 | 22.08 Million USD | 47.97% |
| 2022 Q2 | 7.83 Million USD | 2614.27% |
| 2022 Q1 | -311.69 Thousand USD | -1.4% |
| 2022 FY | 44.83 Million USD | 3979.98% |
| 2022 Q3 | 14.92 Million USD | 90.41% |
| 2021 Q3 | -299.74 Thousand USD | -8.05% |
| 2021 Q4 | -307.4 Thousand USD | -2.56% |
| 2021 Q1 | -8326.00 USD | 0.0% |
| 2021 Q2 | -277.42 Thousand USD | -3232.0% |
| 2021 FY | -1.15 Million USD | -1387.0% |
| 2020 FY | -77.71 Thousand USD | -108.19% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | -37.33 Thousand USD | 23.72% |
| 2019 Q2 | - USD | 0.0% |
| 2018 FY | -48.93 Thousand USD | -14.99% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 FY | -42.55 Thousand USD | -107.76% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 FY | -20.48 Thousand USD | -478.32% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 FY | -3542.00 USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 98.394% |
| Dynavax Technologies Corporation | 182.11 Million USD | -34.274% |
| Illumina, Inc. | 2.74 Billion USD | 91.088% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 95.332% |
| Biogen Inc. | 7.3 Billion USD | 96.651% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 2656.293% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 88.726% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 77.627% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 53.31% |
| Waters Corporation | 1.76 Billion USD | 86.115% |
| Perrigo Company plc | 1.68 Billion USD | 85.448% |
| uniQure N.V. | 2.21 Million USD | -10939.955% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -1311.946% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 32.454% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 78226.198% |
| bluebird bio, Inc. | -4.03 Million USD | 6167.866% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -1552.934% |
| Imunon, Inc. | -720 Thousand USD | 34062.959% |
| Myriad Genetics, Inc. | 476.4 Million USD | 48.67% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 86.763% |
| Nektar Therapeutics | 53.47 Million USD | -357.263% |
| Editas Medicine, Inc. | -99.52 Million USD | 345.695% |
| Verastem, Inc. | -62 Thousand USD | 394511.29% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.078% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 884.579% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -2335.122% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 1341.357% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 87.159% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 639.515% |
| Evolus, Inc. | 140.52 Million USD | -74.014% |
| Adicet Bio, Inc. | -6.09 Million USD | 4110.085% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 386.959% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 97.836% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -234.672% |
| FibroGen, Inc. | 128.9 Million USD | -89.703% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 92.943% |
| OPKO Health, Inc. | 318.12 Million USD | 23.133% |
| Homology Medicines, Inc. | -7.22 Million USD | 3482.695% |
| Geron Corporation | -123.5 Million USD | 297.999% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 83.89% |
| Exelixis, Inc. | 1.75 Billion USD | 86.087% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 83844.863% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 161.319% |
| Zoetis Inc. | 5.83 Billion USD | 95.808% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -80871.854% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 97.159% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 80804.62% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 68.59% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 48.616% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 61.605% |
| Blueprint Medicines Corporation | 236.58 Million USD | -3.361% |
| Insmed Incorporated | 239.63 Million USD | -2.045% |
| TG Therapeutics, Inc. | 219.1 Million USD | -11.605% |
| Incyte Corporation | 3.44 Billion USD | 92.893% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 28.894% |